"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 2 | 8 |
| 1996 | 7 | 2 | 9 |
| 1997 | 17 | 2 | 19 |
| 1998 | 17 | 2 | 19 |
| 1999 | 11 | 2 | 13 |
| 2000 | 15 | 6 | 21 |
| 2001 | 10 | 5 | 15 |
| 2002 | 15 | 5 | 20 |
| 2003 | 20 | 5 | 25 |
| 2004 | 15 | 10 | 25 |
| 2005 | 29 | 9 | 38 |
| 2006 | 13 | 17 | 30 |
| 2007 | 18 | 21 | 39 |
| 2008 | 32 | 10 | 42 |
| 2009 | 22 | 20 | 42 |
| 2010 | 34 | 16 | 50 |
| 2011 | 39 | 19 | 58 |
| 2012 | 35 | 17 | 52 |
| 2013 | 38 | 24 | 62 |
| 2014 | 38 | 12 | 50 |
| 2015 | 50 | 28 | 78 |
| 2016 | 56 | 23 | 79 |
| 2017 | 39 | 17 | 56 |
| 2018 | 41 | 22 | 63 |
| 2019 | 35 | 17 | 52 |
| 2020 | 39 | 7 | 46 |
| 2021 | 43 | 14 | 57 |
| 2022 | 16 | 2 | 18 |
| 2023 | 22 | 2 | 24 |
| 2024 | 4 | 16 | 20 |
| 2025 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
How I treat acute myeloid leukemia with differentiation therapy. Blood. 2025 Mar 20; 145(12):1251-1259.
-
Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2025 Mar 17; 31(6):965-974.
-
Advancing drug development in myelodysplastic syndromes. Blood Adv. 2025 Mar 11; 9(5):1095-1104.
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
-
Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations. Cancer Discov. 2025 Mar 03; 15(3):511-529.
-
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors. Clin Cancer Res. 2025 Feb 17; 31(4):628-638.
-
Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Adv. 2025 Feb 11; 9(3):473-487.
-
Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. Cell Rep Med. 2025 Feb 18; 6(2):101941.
-
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025 Feb 01; 11(2):136-144.
-
Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease. Arterioscler Thromb Vasc Biol. 2025 Mar; 45(3):372-385.